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The huntingtin N17 domain is a modulator of mutant huntingtin
toxicity and is hypophosphorylated in Huntington’s disease (HD).
We conducted high-content analysis to find compounds that could
restore N17 phosphorylation. One lead compound from this screen
was N6-furfuryladenine (N6FFA). N6FFA was protective in HD
model neurons, and N6FFA treatment of an HD mouse model cor-
rects HD phenotypes and eliminates cortical mutant huntingtin
inclusions. We show that N6FFA restores N17 phosphorylation lev-
els by being salvaged to a triphosphate form by adenine phos-
phoribosyltransferase (APRT) and used as a phosphate donor by
casein kinase 2 (CK2). N6FFA is a naturally occurring product of
oxidative DNA damage. Phosphorylated huntingtin functionally
redistributes and colocalizes with CK2, APRT, and N6FFA DNA ad-
ducts at sites of induced DNA damage. We present a model in
which this natural product compound is salvaged to provide a tri-
phosphate substrate to signal huntingtin phosphorylation via
CK2 during low-ATP stress under conditions of DNA damage, with
protective effects in HD model systems.
DNA repair | oxidation | Huntington’s disease | neurodegeneration |
high-content analysis
Huntington’s disease (HD) is a dominantly inherited neuro-degenerative disorder characterized by late age-onset loss of
cognition, emotional disorder, and loss of motor control. The
disease is caused by a CAG expansion within the first exon of the
HTT gene, which translates to a polyglutamine expansion in
the huntingtin protein (1). Although the expansion of CAG length is
correlated with age of disease onset, individuals with the same
number of CAG repeats may vary in their disease onset by 40 y or
more (2). Genome-wide association studies (GWAS) performed on
large cohorts of HD patients to identify genetic modifiers of disease
onset highlighted DNA-repair pathways, redox control proteins,
and mitochondrial energy metabolism as the major modifiers of the
onset of HD (3, 4). We have since defined huntingtin as a com-
ponent of the ataxia telangiectasia mutated (ATM) DNA damage-
response complex that accumulates at sites of DNA oxidative
damage and as a scaffold for DNA-repair factors (5). Along with
these newly defined functions, huntingtin has also previously been
implicated in vesicular and axonal trafficking, cell division, synaptic
transmission, and the cell stress response (6–11). Reflecting this
variety of functions, the huntingtin protein localizes to several
subcellular compartments. Localization is largely regulated by the
first 17 amino acids of the protein, the N17 domain, which is
phosphorylated at two key residues: serines S13 and S16 (12, 13).
The N17 domain, directly adjacent to the polyglutamine tract,
forms an amphipathic α-helix that reversibly tethers huntingtin to
membranes (7, 14), regulating intracellular localization between
vesicles, the endoplasmic reticulum (ER), the primary cilium,
and the nucleus (15). Huntingtin nuclear localization is primarily
affected by cell stress (7), and the N17 domain is a reactive ox-
ygen species (ROS) sensor, whereby sulfoxidation of the methi-
onine M8 residue promotes the release of huntingtin from
membranes, S13/S16 phosphorylation, and translocation to the
nucleus (11). Deletion of the N17 domain accelerates disease in
mouse and zebrafish models of HD (16, 17), implicating the
domain in disease progression. In HD mouse models, serine
phospho-mimetics (12) or induced serine phosphorylation (18)
can prevent or fully reverse the toxicity of mutant huntingtin,
defining restoration of N17 phosphorylation as a valid subtarget
for HD therapeutic development.
We therefore set out to identify compounds that could modu-
late N17 phosphorylation in an attempt to restore the hypo-
phosphorylation of N17 seen in HD cells (13, 19). Using an
extensively validated antibody against phosphorylated S13 and S16
(13), we conducted a high-content screen for the effects of diverse
small-molecule natural products on N17 phosphorylation. To
minimize investigator bias, we used both blind, automated mi-
croscopy image acquisition and nonsupervised machine sorting of
the images. We identified a number of compounds with known
activities in the context of HD as well as one unique compound,
N6-furfuryladenine (N6FFA), also known as “kinetin.”
N6FFA has been extensively studied (20) and annotated as a
plant cytokine with biological effects in mammalian cells, including
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protection against oxidative stress (21) and delay of age-related
phenotypes in human fibroblasts (22). N6FFA is also a product of
DNA oxidation by ROS (23) and occurs as a normal excreted hu-
man metabolite (24). N6FFA/kinetin was found to be the precursor
to N6FFA/kinetin triphosphate (KTP), an ATP analog produced
upon the salvaging of N6FFA by adenine phosphoribosyltransferase
(APRT) (25). This nucleotide salvaging is important in the context
of HD, where ATP levels are significantly reduced (26), particularly
in neurons which rely heavily on nucleotide salvage as opposed to de
novo nucleotide biosynthetic pathways (27, 28). Further, ATP pro-
duction can halt during DNA-damage repair (29), and free ATP
levels drop significantly during the ER stress response (9). Here, we
show casein kinase 2 (CK2) can use KTP to phosphorylate N17 and
that treatment with the N6FFA precursor molecule is protective in
cell neuronal and animal models of HD.
We propose a model in which this natural product, upon being
salvaged, potentiates the enzymatic phosphorylation reaction on
polyglutamine-expanded huntingtin, allowing proper degrada-
tion of the mutant protein (30). In vivo administration of
N6FFA, a blood–brain barrier (BBB)-permeable molecule (31),
in HD model mice resulted in reduced cortical brain inclusions
in YAC128 mice as well as HD phenotypic reversal.
Results
High-Content Analysis Identifies N6FFA as a Modulator of N17
Phosphorylation. Phosphorylation of huntingtin N17 at S13 and
S16 has been shown to be a beneficial modification in the context of
HD in both cell and animal models (12, 18). To identify modulators
of N17 phosphorylation of huntingtin, we used high-content analysis
to screen a library of 133 natural compounds (Selleckchem) for their
potential effects on the fluorescent signal pattern of anti–N17-
S13pS16p, an antibody recognizing N17 phosphorylated on S13
and S16. This antibody was raised to the phospho-S13/phospho-
S16 epitope and was cross-purified by peptide-affinity chroma-
tography both to the phospho-peptide and against the unmodified
peptide. Specificity and selectivity of this antibody was validated by
peptide dot blot titrations; Western blots to whole-cell extracts of
WT, heterozygous, and homozygous mutant huntingtin cells; im-
munofluorescence with peptide competition and lack of signal in a
huntingtin-knockout mouse model; and embryo fibroblasts by
Western blot (13). Huntingtin recruitment to DNA-damage ad-
ducts, which was visualized by multiple independent huntingtin
monoclonal antibodies, was also demonstrated using this antibody
(5). The antibody was also used to define the phospho-dependent
switch in huntingtin conformation (32), the increased phosphor-
ylation of huntingtin by ganglioside GM1 treatment of mice (18),
and the role of methionine M8 sulfoxidation as a precursor to
N17 phosphorylation (11).
The anti–N17-S13pS16p antibody was directly labeled, and di-
rect immunofluorescence was performed on STHdhQ7/Q7 cells (33)
treated with a library of 133 compounds. Images were taken in an
unbiased manner with a 40× objective at five software-randomized
locations per well with hardware autofocus. There was no in-
vestigator observation beyond the first well, where exposure levels
were set within the camera dynamic range.
The 12-bit depth images were analyzed by PhenoRipper soft-
ware (34) in a single channel by assaying image textures. These are
a set of pixel-level and space metrics calculated in image process-
ing, designed to quantify the perceived texture of an image. Phe-
noRipper measures multiple bitmap texture elements in each
image, defines the three most variant textures, and uses these three
variances to plot a vector in unitless 3D space without any pre-
determined parameters so that the points farthest from one an-
other represent the most dissimilar images within that dataset. The
plot is generated by principal component analysis (PCA) within the
dataset and thus has no units on the axes. Hits were chosen based
on which compounds plotted furthest from the vehicle control,
0.01% DMSO (Fig. 1A). A summary of these of hits, shown in SI
Appendix, Fig. S1A, includes several antiinflammatory, antioxidant,
and apoptosis-inducing compounds as well as several compounds
that did not fall into any specific category (summarized in Fig. 1B).
Antioxidant compounds plotted distinctly from vehicle control, as
is consistent with our previous study, which defined methionine
M8 sulfoxidation as a trigger of S13/S16 phosphorylation by af-
fecting N17 helicity (11). Another distinct group of compounds was
annotated as antiinflammatories. This is consistent with our results
from another previous study implicating the IKKβ pathway in reg-
ulating huntingtin phosphorylation (13), which has been previously
defined by Thompson et al. (30) as the trigger for huntingtin deg-
radation. One of the most distant hit compounds from the control
that did not plot near any antiinflammatories or antioxidants had
the most effect in the system: N6FFA (Fig. 1C). N6FFA is a BBB-
permeable compound (31, 35) with a potent effect on the phospho-
N17 signal. We therefore selected N6FFA for further investigation.
N6FFA Increases Phosphorylation of N17 in Cells Expressing Mutant
Huntingtin and Is Protective in Cell Models of HD. To further un-
derstand the effects of N6FFA, we directly examined the phos-
phorylation state of N17 by immunoblot in mouse striatal-derived
cells expressing either WT or humanized mutant huntingtin
[STHdhQ7/Q7 and STHdhQ111/Q111, respectively (33)] with increasing
doses of N6FFA. In WT cells treated with N6FFA, we observed a
modest increase in N17 phosphorylation that did not reach signifi-
cance (Fig. 1D). This modest increase was amplified by the more
sensitive immunofluorescence technique used in the initial screen in
which N6FFA was identified as a hit. In contrast, when we tested the
effect of N6FFA on HD-knockin homozygote model cells expressing
expanded huntingtin (STHdhQ111/Q111), we observed a robust and
statistically significant increase in N17 phosphorylation (Fig. 1E). The
optimal treatment concentration was between 0.5–1 μM for a time of
24 h. These results validated N6FFA as a hit from the high-content
analysis screen and a modulator of N17 phosphorylation.
As phosphorylation of mutant huntingtin is a protective modi-
fication (16, 18), we next asked whether N6FFA affected cell vi-
ability. We found that N6FFA was protective in STHdhQ111/Q111
cells against serum starvation-induced stress, with a significant
reduction in annexin V staining noted at a concentration of
10 μM, as shown in SI Appendix, Fig. S1B. This effect was not seen
in STHdhQ7/Q7 cells. Previous studies have reported substantially
different thresholds for N6FFA cytotoxicity, with some groups
reporting decreased cell viability at doses as low as 500 nM (36)
and others seeing a decrease in viability at doses as high as 100 μM
(37). As this difference in N6FFA toxicity threshold may be due to
cell-type differences, we sought to test the protective effects of this
compound against mutant huntingtin-induced toxicity in a more
disease-relevant cell type: mouse primary cortical neurons. We
transfected mouse embryonic cortical neurons with a fragment of
huntingtin (amino acids 1–586) containing either a WT polyglut-
amine length of 22 aa (N586-HttQ22) or a mutant polyglutamine
length of 82 aa (N586-HttQ82) to assay cell death (38) and treated
these cells with increasing concentrations of N6FFA. There was a
significant protective effect in cells expressing polyglutamine-
expanded huntingtin at 1 μM and 10 μM N6FFA (Fig. 1F), con-
sistent with the dose–response curves assaying mutant huntingtin
phosphorylation in mouse striatal-derived cells (Fig. 1E). We saw
no significant effect of N6FFA in the neurons expressing WT
huntingtin at any of the concentrations tested (Fig. 1F).
Thus, we have identified N6FFA as a compound that affects
N17 phosphorylation and promotes cell viability in a dose-
dependent manner in mutant huntingtin-expressing cells.
N6FFA Treatment Reduces Cortical Mutant Huntingtin Inclusions and
Improves Phenotypes in an HD Mouse Model. Having determined
that N6FFA was protective in an HD neuronal model, we next
tested the effect of N6FFA on the motor phenotypes of the
YAC128 HDmouse model (39). This is a transgenic mouse model






















in which a full-length copy of human huntingtin bearing 128 CAG
repeats is expressed on a yeast artificial chromosome (YAC). Mice
were i.p. injected with N6FFA daily at ∼8 mo of age. As this
modality is highly stressful, with mice being handled and receiving
painful injections regularly, all mice lost body weight during the
course of the treatment (SI Appendix, Fig. S2A). Motor tests, but
not anxiety tests, were therefore pursued in this experiment. While
YAC128 mice performed significantly worse than WT littermates
on both the accelerating and fixed rotarod motor coordination
assays as determined by two-way ANOVA, YAC128 mice that
received i.p. injection of N6FFA exhibited increased latency to fall
for both tests (accelerating rotarod: effect of genotype, F1,26 =
11.86, P = 0.002; effect of treatment, F2,26 = 4.974, P = 0.015; fixed
rotarod: effect of genotype, F1,26 = 5.542, P = 0.026; effect of
treatment, F2,26 = 11.94, P = 0.0002) (Fig. 2 A and B). The motor
behavior of YAC128 mice, as measured by the narrow beam test,
was also improved with N6FFA treatment (Fig. 2C). There was
also some improvement in motor phenotypes in WT control mice
upon N6FFA dosing. This is consistent with the effects of N6FFA
on WT huntingtin phosphorylation (Fig. 1C) and with the primary
screen assaying WT huntingtin (Fig. 1A).
To observe the effects of N6FFA in a modality that was less
stressful, allowing acquisition of more reliable data related to
anxiety-like behavior, as well as being more amenable to patient
treatment, we dosed the animals orally at ∼9 mo of age with
N6FFA added to chow for 49 d. At this lower dose and oral mo-
dality, no motor-correction effects were noted. We then assessed
the effect of N6FFA oral dosing on YAC128 anxiety phenotypes,
given that this modality did not inflict a pain stress on the mice.
While YAC128 mice spent more time in the closed arms of the
elevated plus maze than WT mice (effect of genotype, F1,30 =
5.670, P = 0.02), indicating increased anxiety, N6FFA treatment
did not correct this behavior (Fig. 2D). On the other hand, N6FFA
decreased anxiety behavior and restored exploratory activity in the
first 5 min of the open field arena test (effect of treatment, F1,33 =
11.26, P = 0.002) (Fig. 2E). We next measured fecal boli dropped
in conditions that elicit anxiety. In the forced swim test,
YAC128 mice released more fecal pellets than WT littermates, an
indication of increased anxiety that was reversed by the adminis-
tration of N6FFA (effect of genotype, F1,34 = 5.773, P = 0.02; effect
of treatment, F1,34 = 3.896, P = 0.05) (Fig. 2F). In summary,
N6FFA improved YAC128 motor phenotypes by i.p. administra-
tion, and anxiety-like phenotypes by oral administration.
We next asked whether the effect of N6FFA on YAC128
phenotypes is due to a direct effect on the huntingtin protein. We





































































































































Fig. 1. Identification and validation of N6FFA as a modulator of N17 phosphorylation. Cells were methanol fixed and stained with a primary conjugate
antibody recognizing N17 with phospho-groups at S13 and S16 (N17-S13pS16p). Five images per well were taken with a 40× air objective. Images were
analyzed by PhenoRipper open source software. A unitless PCA plot and a summary of hits are presented in A and B, respectively. Compound 134, indicated by
a red arrow, represents vehicle control; compound 50, encircled in green, represents N6FFA. (C) Chemical structure of N6FFA. (D and E) STHdhQ7/Q7 (D) and
STHdhQ111/Q111 (E) cells were treated with the indicated concentrations of N6FFA for 24 h, and total cell lysates were separated by SDS/PAGE followed by
immunoblotting with N17-S13pS16p antibody. Pixel intensity results from three independent replicates were quantified. Asterisks indicate concentrations of
N6FFA that significantly increased N17 phosphorylation compared with control as determined by an unpaired two-tailed t test (*P < 0.05). Bars represent
mean values ± SEM. (F) Mouse cortical neurons were transfected with N586-HttQ22 or N586-HttQ82 and were treated with various concentrations of N6FFA.
A nuclear condensation assay was performed to determine percent of cell death. Asterisks indicate concentrations of N6FFA that significantly decreased cell
death as determined by an unpaired two-tailed t test from three independent replicates (*P < 0.05; **P < 0.001).





























the brains of control-treated and N6FFA-treated YAC128 mice.
As shown in Fig. 2G, upon N6FFA treatment the levels of in-
soluble mutant huntingtin protein were dramatically decreased in
the cortex but not in the striatum (Fig. 2H). While we hypothesize
that this difference may be due to incomplete delivery of N6FFA
to the striatum, with most of the compound metabolized in the
cortex, as directed by cerebrospinal fluid flow, we have not in-
vestigated this phenomenon further. We also investigated levels of
insoluble mutant huntingtin in the striatum and cortex of the mice
that received i.p. injections of N6FFA. In the cortex, we again see
significantly decreased levels of insoluble huntingtin; in the stria-
tum, a trend toward decreased levels of insoluble mutant hun-
tingtin did not reach significance (SI Appendix, Fig. S2 B and C).
Thus, we observed protective effects of N6FFA in HD cell and
mouse models, with direct effects on huntingtin protein levels.
The Metabolic Product of N6FFA/Kinetin, KTP, Can Be Used as a
Phospho-Donor by CK2 to Phosphorylate N17. We next evaluated
possible mechanisms of N6FFA action. Cells can metabolize
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Fig. 2. Effects of N6FFA administration on motor performance, anxiety-like behavior, and huntingtin inclusions in YAC128 mice. (A) Mice were tested on an
accelerating rotarod (4–40 rpm in 2 min) after 42 d of daily i.p. injection of N6FFA or vehicle (1.5% DMSO). (B) Mice were tested on a fixed-rate rotarod
(12 rpm) after 42 d of i.p. injection of N6FFA or vehicle. In A and B n = 7 for WT DMSO, and n = 5 for WT N6FFA (0.83 mg/kg and 4.17 mg/kg), YAC128 DMSO,
and YAC128 N6FFA (0.83 mg/kg and 4.17 mg/kg). (C) Mice were tested in the narrow beam test. n = 6 for WT DMSO, WT N6FFA 4.17 mg/kg, and YAC128
N6FFA 4.17 mg/kg; n = 5 for WT N6FFA 0.83 mg/kg, YAC128 DMSO, and YAC128 N6FFA 0.83 mg/kg. (D) Time in the closed arms of the elevated plus maze was
tested. n = 10 for WT control and for WT N6FFA; n = 7 for YAC128 control and for YAC128 N6FFA. (E) Exploratory activity in the first 5 min spent in an open
field arena is shown. n = 10 for WT control and for WT N6FFA, n = 8 for YAC128 control, and n = 9 for YAC128 N6FFA. (F) The number of fecal pellets released
in the forced swim test was measured. n = 10 for WT control and for WT N6FFA; n = 9 for YAC128 control and for YAC128 N6FFA. (G and H) SDS-insoluble
aggregates of mutant huntingtin were measured in YAC128 cortex (G) or striatum (H) after treatment with control or N6FFA-containing diet (n = 8 for
YAC128 control diet; n = 7–9 YAC128 N6FFA diet). Representative membranes and pixel intensity analysis are shown (*P < 0.05). Statistical analysis was
performed using two-way ANOVA and Bonferroni posttest for mouse performance and Student’s t test for insoluble mutant huntingtin data. In all panels,
error bars represent mean ± SEM.






















nucleotide-salvaging enzyme APRT (25). The resulting ATP
analog, KTP (SI Appendix, Fig. S3A), can be used by PTEN-
induced putative kinase 1 (PINK1) for the transfer of its
gamma-phosphoryl group to the PINK1 substrate (25). The ki-
nase CK2 can utilize multiple substrates as phospho-donors,
including GTP and ATP (40). We have previously reported
that CK2 is a putative N17 kinase, based on results of a kinase
inhibitor screen with multiple CK2 inhibitors as hits (13). More
precise effects were achieved by treatment with nanomolar levels
of the CK2 inhibitor DMAT (41), with inhibition of CK2 spe-
cifically decreasing phosphorylation of N17 (13). We therefore
hypothesized that the mechanism by which N6FFA increases
N17 phosphorylation is through its metabolism to KTP and use
by CK2 as a phospho-donor for huntingtin N17.
To test whether CK2 can use KTP to phosphorylate its ca-
nonical substrates, we performed a peptide array assay com-
paring CK2 kinase activity with either ATP or KTP as phospho-
donors. A full table of these peptides is presented in SI Appendix,
Fig. S3. As shown in SI Appendix, Fig. S3B, CK2 phosphorylates
numerous substrates to similar degrees using either ATP or KTP.
We next asked whether CK2 can directly phosphorylate the
N17 domain in vitro. We found that CK2 can use either ATP or
KTP to phosphorylate N17, provided that S13 is already primed by
phosphorylation (Fig. 3 A and B). This is consistent with the de-
scription of CK2 as a ubiquitous acidophilic kinase, where its activity
is typically regulated by the substrate and priming adds a negative
charge to the site (42). To confirm that the effect we are seeing is
mediated by CK2, we treated cells with N6FFA in the presence
of DMAT (41). DMAT prevented N6FFA from modulating N17
phosphorylation levels (Fig. 3C), consistent with previous work that
defined CK2 as a N17 kinase (13). Thus, the restoration of
N17 phosphorylation by N6FFA can be blocked by the inhibition
of CK2.
To form KTP for utilization by CK2, N6FFA must be salvaged
to the triphosphate form. To test if N6FFA salvaging to KTP is
critical for the observed increase in N17 phosphorylation, we
treated cells with 9-diaza-kinetin (9DK), a derivative of N6FFA
that cannot be salvaged due to a nonhydrolysable nitrogen–nitro-
gen diaza-bond at nitrogen nine (structures are shown in Fig. 3D).
In contrast to N6FFA, 9DK did not cause an increase in huntingtin
phosphorylation in STHdhQ111/Q111 cells (Fig. 3D), indicating that
the increase in N17 phosphorylation upon N6FFA treatment oc-
curs through its conversion to KTP by nucleotide salvaging.
Components of the N6FFA Salvaging and Signaling Pathway Functionally
Colocalize at Sites of DNA Damage. CK2 is a constitutively active ki-
nase regulated, in part, by subcellular localization and proximity to
its substrates (43). CK2 is well characterized to phosphorylate
DNA-repair factors (44), and we previously defined huntingtin at
sites of ATM-mediated DNA repair (5). We therefore asked
whether CK2 and huntingtin colocalize within the cell both at
resting states and during active DNA-damage repair. We have
previously reported that the anti–N17-S13pS16p antibody highlights
insoluble, chromatin-dependent nuclear puncta (5, 11, 13), which
we recently identified as nuclear speckles (19). Using antibodies
against CK2 and N17-S13pS16p and superresolution structured il-
lumination microscopy (SR-SIM), we observed colocalization of
these endogenous proteins at nuclear speckles (Fig. 4A), suggesting
that CK2 kinase activity on N17 may take place in the nucleus,
similar to CK2 activity on DNA-repair proteins (45) such as
XRCC1 (46) or P53BP1 (47).
N6FFA is an endogenous byproduct of oxidative DNA dam-
age, whereby the addition of a furfuryl group to an adenosine
base within the DNA backbone under Fenton reaction-oxidizing
conditions generates N6FFA riboside (23). The generation of
this adduct is followed by excision of N6FFA from the DNA
backbone (48). We have shown that the huntingtin protein acts
as a scaffold for DNA-repair proteins in response to oxidative
stress (5). The importance of this role was given context when
the results of a large GWAS study revealed a high number of
DNA-repair genes as modifiers of age of disease onset (3).
Similar to the protective effects we observed in HD model mice
(Fig. 2), a recent study showed neuroprotective effects of N6FFA
against radiation-induced behavioral changes in a Swiss albino
mouse model (49). Together, these findings prompted us to in-
vestigate a connection between N6FFA and huntingtin in the
context of DNA damage.
We first asked whether we could directly detect N6FFA riboside
and the nucleotide-salvaging protein APRT at sites of DNA dam-
age where huntingtin is known to accumulate (5). Using a 405-nm
laser, we induced DNA damage in a line across chromatin. Af-
ter 20-min incubation, endogenous CK2 and huntingtin phos-
phorylated at N17 were enriched at the irradiated regions of DNA
damage (Fig. 4B). Unlike steady-state imaging at nuclear puncta,
this functional relocalization with colocalization was triggered by
induced DNA damage. While protein colocalization alone is not
definitive of interactions, the functional colocalization of these
proteins supports the concept that they are functioning as part of a
complex relevant to functions in DNA-damage repair. Further-
more, both the oxidative DNA-damage product, N6FFA riboside
(Fig. 4C), and the salvaging enzyme responsible for converting this
product to KTP, APRT (25) (Fig. 4D), concentrated at the same
DNA-damage sites. Thus, components of the N6FFA salvaging
pathway functionally colocalize to sites of DNA damage.
We previously found that huntingtin localization to sites of DNA
damage is dependent on ATM kinase activity (5). We therefore





Fig. 3. CK2 uses KTP as a phospho-donor to phosphorylate huntingtin
N17 when primed by phosphorylation. (A and B) Representative blot (A) and
quantification (B) of an in vitro N17 phosphorylation assay using CK2 with
either ATP or KTP as phospho-donor. **P < 0.001, Mann–Whitney test; n =
3 independent replicates. (C) Representative blot (Upper) and quantification
(Lower) of N17-S13pS16p levels in STHdhQ111/Q111 cells upon treatment with
N6FFA with or without the addition of the CK2 inhibitor DMAT (4.5 μM).
*P < 0.05, Mann–Whitney test (n = 4 independent replicates). (D) Repre-
sentative blot (Upper) and quantification (Lower) of N17-S13pS16p levels in
STHdhQ111/Q111 cells upon treatment with the nonhydrolysable N6FFA de-
rivative 9DK (analysis by Mann–Whitney test) (Left) or treatment with N6FFA
(analysis by unpaired t test) (Right). n = 3 independent replicates for both
experiments; *P < 0.05. For all data, error bars show mean ± SEM.





























As shown in Fig. 4D, APRT could still localize to UV irradiation
sites in the presence of the ATM inhibitor KU55933 (50) under
conditions that inhibit huntingtin recruitment. This suggests that
recruitment of the nucleotide salvager APRT to DNA-damage sites
and KTP generation do not require ATM activation, and hence do
not require huntingtin recruitment. CK2 is required for P53BP1
accumulation at sites of DNA damage, which is a prerequisite for
efficient activation of the ATM-mediated signaling pathway (47).
Huntingtin makes up part of the ATM complex, and its recruitment
to DNA damage is blocked by ATM kinase inhibition (5). These
results allow us to hypothesize a mechanism in which KTP, pro-
duced proximal to DNA damage via APRT activity, is used by
CK2 to phosphorylate substrates in the ATM DNA damage-repair
response, including the huntingtin N17 domain. Thus, this salvaged
product of oxidative DNA damage may act as a signaling molecule
to potentiate DNA repair (Fig. 5) under the repair-associated
conditions of a low-ATP “energy crisis” (29).
Discussion
Many current drug-discovery efforts are limited to high-
throughput analysis with low-resolution endpoints (51). As an
alternative, we used high-content analysis to screen a small li-
brary of natural compounds encompassing a wide breadth of bio-
logically active chemical space to define modulators of N17
phosphorylation. We show that high-content analysis of endog-
enous phosphorylated huntingtin is extremely effective for
identifying potential disease-modifying compounds. The use of
PCA and image textures allowed us to visualize the degree to
which compounds affected N17-S13pS16p signal properties
without bias, in that we did not predefine any parameters for
sorting. We found that the two predominant types of compounds
affecting our assay were antiinflammatory agents and antioxi-
dants. Consistent with this finding, we and others have previously
shown that inhibition of IKKβ within the NF-κB inflammation
pathway affects huntingtin phosphorylation (13, 30).
The identification of antioxidants as modulators of N17 phos-
phorylation is also compelling, given the implication of ROS in HD
pathology (52). The antioxidant XJB-5-131 is known to modify
toxicity in an HD model, by either preventing onset or improving
pathophysiology in a mouse that has developed disease (53). Our
group has recently shown that huntingtin acts as an ROS sensor,
elucidating a mechanism by which sulfoxidation of methionine
eight within N17 leads to increased huntingtin solubility from lipid
membranes of the ER, enhancing S13/S16 phosphorylation and
translocation of huntingtin to the nucleus (11). The identification
of several antioxidant compounds in our screen supports these
findings, as these compounds reduced the phospho-N17 signal. In
the context of ROS, increased N17 phosphorylation upon IKKβ
inhibition may be due to the prevention of the NF-κB pathway
ROS signaling response and the resulting elevated intracellular
ROS levels (54).
The N6FFA compound was selected for further experimen-
tation as it has been demonstrated in animal models to be both
BBB permeable (31) and neuroprotective (49). We show a















Fig. 5. A product of oxidative DNA repair is used by CK2 to phosphorylate
huntingtin at sites of DNA damage. DNA is oxidized via the Fenton reaction
by age-onset reactive oxygen stress. N6-furfuryladenine riboside results and
is excised by the DNA damage-repair machinery. APRT salvages the excision
product, N6FFA, to yield KTP. KTP is used as a phosphate donor by
CK2 to modify huntingtin N17, and potentially other DNA-repair proteins,
in a positive-feedback mechanism. We hypothesize that exogenous ad-
ministration of N6FFA potentiates the reaction. All components of the
model seen to functionally colocalize proximal to DNA-damage regions are
highlighted in green.





















Fig. 4. Components of the N6FFA–APRT–KTP–CK2–huntingtin pathway
colocalize at sites of DNA damage. (A, Upper) Human fibroblasts were
stained with anti-CK2 (green) and anti–N17-S13pS16p (magenta) and were
imaged using SR-SIM. (Lower) Magnified views of the boxed areas. (Scale
bar: 1 μm.) (B) Human fibroblasts were irradiated with a 405-nm laser in the
indicated region to induce DNA damage. After a 20-min incubation period,
immunofluorescence was performed against CK2 (green) and N17-S13pS16p
(magenta), and the x and y coordinates were revisited to image the irradi-
ated cells by Z-stacked wide-field microscopy and deconvolution. We ob-
served a 100% correlation between CK2 and N17-S13pS16p localization to
irradiated regions in two experiments (n = 20–30 cells per experiment). (C)
Human fibroblasts were irradiated as in B, stained with anti-N6FFA riboside
(green), and imaged by Z-stacked wide-field microscopy and deconvolution.
(D) Human fibroblasts were treated with vehicle control (mock) or 10 μM
KU55933 for 25 min and then were irradiated as in B, stained with anti-APRT
(green) and anti–N17-S13pS16p (magenta), and imaged by Z-stacked wide-
field microscopy and deconvolution. (Scale bars: 10 μm in B–D.)






















mutant huntingtin fragment in cortical neuronal culture. This is
consistent with other studies showing protective effects of
N6FFA under conditions of stress (22, 36, 49, 55, 56). N6FFA
has been broadly categorized as an antioxidant (21); however, we
note that N6FFA increases huntingtin phosphorylation, whereas
antioxidants decrease phosphorylation (11). More recent studies
have shown that N6FFA is not effective in scavenging free rad-
icals (55) but instead activates other antioxidant defense mech-
anisms (36, 37, 55, 56). Our results support an alternative
mechanism in which huntingtin is directly modified by N6FFA.
We observed reduced cortical mutant huntingtin aggregate
load upon N6FFA treatment in YAC128 mice. Previous findings
have shown that mutant huntingtin is not properly degraded,
leading to toxic accumulation (57). Studies have shown that
phosphorylation of huntingtin mediates clearance (30, 58, 59)
and that mutant huntingtin is hypophosphorylated at many sites
of proteolytic activity (60). Huntingtin N17 phosphorylation
enhances protein clearance by the proteasome and lysosome
(30). Our results are consistent with increased mutant huntingtin
phosphorylation, via administration of N6FFA, mediating pro-
tein clearance. With the efficacy of N6FFA established, we next
sought to determine the mechanism.
The report that the metabolic product of N6FFA, KTP, is an
ATP analog that can be utilized by PINK1 as a phospho-donor
(25) prompted us to investigate a similar mechanism for CK2,
which we previously identified as a regulator of N17 phosphor-
ylation (13). CK2 exhibits unusual catalytic-site flexibility and is
one of the few known kinases that can use both ATP and GTP
as phosphate donors (42). We found that CK2 can also use KTP
to phosphorylate its substrates, including N17. Furthermore,
N17 phosphorylation was not achieved with a nonhydrolyzable
N6FFA derivative or in the presence of a CK2 inhibitor, impli-
cating nucleotide-salvaging activity and CK2 activity as crucial
elements of the N6FFA effect. As KTP is also used by PINK1 to
regulate mitochondrial proteostasis, and enhanced mitochon-
drial proteostasis is protective against β-amyloid proteotoxicity
(61), some pleiotropy of KTP-mediated signaling could be ben-
eficial beyond just phospho-huntingtin correction.
We found that CK2 colocalizes with N17-phosphorylated
huntingtin at nuclear speckles. CK2 is a ubiquitous kinase
known to modify proteins involved in DNA repair (46, 62), and
huntingtin is part of the ATM oxidative DNA damage-response
complex (5). The influence of DNA-repair pathways on HD
disease onset, revealed by GWAS (3, 4, 63), suggests that ROS
and DNA-damage repair are critical modifiers for HD age of
onset. CK2 may be phosphorylating huntingtin N17 at these
nuclear puncta in response to oxidative DNA damage. This is
similar to the way CK2 phosphorylates the deubiquitinating en-
zyme OTUB1, mediating its nuclear entry and the formation of
P53BP1 DNA-repair foci (64).
N6FFA riboside is a known product of oxidative DNA damage
via the Fenton reaction, causing perturbation of the DNA
structure (48, 65). Upon induction of DNA damage via 405-nm
laser, we detected N6FFA riboside generated within the DNA.
We propose that, following excision from the DNA, N6FFA is
salvaged to KTP via the mechanism proposed by Hertz et al.
(25). The accumulation of huntingtin, CK2, N6FFA, and the
nucleotide salvager APRT at DNA-damage sites suggests that
the effective local concentration of these pathway factors in
proximity to DNA damage facilitates phosphorylation of N17.
In HD, KTP-mediated signaling immediately proximal to
DNA damage may be important in the context of low ATP.
Aging cells demonstrate significantly decreased ATP levels (66),
a condition that is exacerbated in HD (26, 67). The role of
huntingtin as a stress-response protein (11, 13, 68) also suggests
that a signaling pathway utilizing an alternate source of phos-
phates may be critical under stress conditions, where most ATP
is utilized at the ER lumen for the unfolded protein response
(69), which is chronically active in HD (70). The energy deficits
seen classically in HD may also be the result of chronic DNA-
damage repair, triggered by age-onset ROS stress: The first step
of DNA single-strand break damage repair is identification of
the lesion by the poly (ADP ribose) polymerase proteins, or
PARPs. PARP hyperactivation during DNA damage can result
in a cellular energy crisis in which poly (ADP ribose) inhibits
ATP production (29). Finally, salvaged purines may be the only
potential source of triphosphate in proximity to DNA-damage
complexes. Neurons rely heavily on the salvaging rather than de
novo synthesis of nucleotides (27, 28), and a recent GWAS
identified RRM2B/P53R2, a ribonucleotide-salvaging enzyme,
as a modifier of HD age of onset. This highlights a potential
important role of salvage pathways in HD (3).
The large number of neurodegenerative disorders for which a
DNA-repair protein is defective, suggests that DNA repair may be
a critical node for neuronal health, particularly at the ATM com-
plex (71). Given the role of huntingtin as a scaffold for the ATM
complex (5), dominant mutant huntingtin effects coupled with an
age-related ROS increase could lead to the age-onset accumulation
of DNA damage. As mutant huntingtin is hypophosphorylated at
the N17 domain (13, 19), and phosphorylation is beneficial in HD
models (12, 18), the effects we observed with N6FFA treatment
connect DNA-damage repair, altered bioenergetics, and mutant
huntingtin phosphorylation and inclusion load.
Materials and Methods
Reagents and Antibodies. All reagents were from Sigma-Aldrich unless oth-
erwise stated. Polyclonal antibody against huntingtin phosphorylated at
S13 and S16 of the N17 domain (anti–N17-S13pS16p) was previously char-
acterized and validated (13). To directly conjugate the anti–N17-S13pS16p
antibody to Alexa Fluor 488 succinimidyl ester dye (Molecular Probes/Life
Technologies), 1 μL dye/10 μL antibody and 5% NaHCO3 were incubated
overnight at 4 °C with rotation. The conjugate antibody was then run through
a Sephadex G-25 bead (Amersham Pharmacia Biotech AB) column and col-
lected by elution with PBS until the visible dye front reached the base of the
column. Additional antibodies used in this study were anti–N17-S13pS16p
(New England Peptides), anti-CK2 alpha (Abcam), and anti-N6FFA/kinetin
riboside (Agrisera) for immunofluorescence and anti-thiophosphate ester
(Abcam), anti-GAPDH (Abcam), rabbit anti-huntingtin (PW0595; Enzo Life
Sciences), and mouse anti-polyglutamine (mAB1574, Chand mouse anti-
huntingtin) for Western blots. Secondary antibodies against rabbit, mouse,
and goat IgG, conjugated to Alexa Fluor 488, 555, 594, or Cy5, were from
Invitrogen. Secondary HRP conjugates were from Abcam. Goat anti-rabbit
IRDye 800CW, goat anti-rabbit IRDye 680CW, and goat anti-mouse IRDye
800 were from LI-COR Biosciences.
Cells. Cells derived from mouse striatum, STHdhQ7/Q7 and STHdhQ111/Q111 (a
kind gift from Marcy E. Macdonald, Massachusetts General Hospital/Harvard
Medical School), were grown in DMEM with 10% FBS at 33 °C in a 5% CO2
incubator. Human hTERT-immortalized foreskin fibroblast BJ-5ta cells
(ATCC) and primary human fibroblasts from Coriell Institute for Medical
Research Biorepositories (ND30014 WT fibroblasts bearing 21/18 CAG re-
peats in HTT gene alleles) were grown in minimal Eagle’s medium with 15%
FBS and 1% Glutamax at 37 °C with 5% CO2. All media and supplements
were from Gibco Life Technologies. Primary cortical neurons were prepared
from CD1 mice as described (38). In brief, cortices of E15 DC1 embryos were
dissected, quickly dissociated, and plated at 1.105 cells/mm2. Cells were kept
in Neurobasal medium supplemented with B27 and 2 mM GlutaMAX (Gibco)
in 5% CO2 at 37 °C throughout the experiment.
High-Content Screen and Analysis. STHdhQ7/Q7 cells were seeded into 96-well
ibiTreat dishes (Ibidi) and grown for 24 h before treatment with a 133-
compound natural-compound library (Selleckchem) for 6 h at 33 °C. Immu-
nofluorescence was performed as described below with Alexa Fluor 488-
conjugated anti–N17-S13pS16p antibody at 1:15 dilution. Images taken
with a 40× objective were analyzed using PhenoRipper (34) in which five
images per well were thresholded by random sampling and analysis was
carried out using a block size of 15. Hits were scored by selecting the points
on the resulting PCA plot lying furthest from controls (outside an arbitrarily
defined radius).





























Compound Administration to Cells. All compounds were administered in
DMEM with 0.2% FBS for 24 h unless otherwise indicated.
Protein Extraction and Immunoblotting. Cells were lysed in either Nonidet P-
40 lysis buffer [50 mM Tris·HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40] or
radioimmunoassay lysis buffer [50 mM Tris·HCl (pH 8.0), 150 mM NaCl, 1%
Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EDTA] containing protease
and phosphatase inhibitors (Roche). Lysates were centrifuged at 17,000 × g
for 12 min, and the supernatant was collected for immunoblot analysis.
Equal amounts of protein were separated by SDS/PAGE on precast 4–20%
polyacrylamide gradient gels (Bio-Rad) and were electroblotted onto
Immobilon PVDF membrane (EMD Millipore). Membranes were blocked in
Tris-buffered saline with Tween 20 (TBST) [50 mM Tris·HCl (pH 7.5), 150 mM
NaCl, 0.1% Tween-20] containing 5% nonfat dry milk for 1.5 h at room
temperature, followed by overnight incubation with primary antibodies
diluted in blocking buffer (anti–N17-S13pS16p 1:2,500; anti-GAPDH 1:7,500)
at 4 °C. After three 15-min TBST washes, membranes were incubated with
HRP-conjugated secondary antibodies diluted in blocking buffer (1:50,000)
for 45 min at room temperature and were visualized using Immobilon en-
hanced chemiluminesence HRP substrate (EMD Millipore) on a MicroChemi
system (DNR Bio-imaging Systems). Bands were quantified using NIH ImageJ
software and were normalized to GAPDH controls.
In Vitro Kinase Assays. GST-CK2α was purified from bacterial culture as pre-
viously described (72). Enzyme concentration was determined by absorbance
at 595 nm, measured on a Victor3 V 1420 multilabel counter (Perkin-Elmer)
using BSA standards. The enzyme was diluted (up to 1:5,000) in CK2 dilution
buffer [5 μΜ Mops (pH 7.0), 200 mM NaCl, 1 mg/mL BSA] immediately before
use in kinase assays.
For the CK2 phospho-donor specificity assay, peptide arrays were syn-
thesized using SPOT technology on nitrocellulosemembranes using the Auto-
Spot Robot ASP 222 (Abimed) as previously described (73, 74). Filters bearing
CK2 substrate sequences and controls were moistened with 95% ethanol to
ensure solubilization of the peptides on the filter; then an equal volume of
water was added with rocking for 15 min. Membranes were washed five
times with water and once with kinase assay buffer (KAB) [50 mM Tris·HCl
(pH 7.5), 30 mM MgCl2, 50 mM KCl] and were incubated in KAB overnight
with gentle rocking. Fresh KAB was added for 1 h at 30 °C with rocking. Then
100 μM ATPγS or KTPγS (Biolog) was added, followed by 100 μM BSA, and
the reaction was started by adding CK2α holoenzyme (1:2,500, 32.44 mg/mL
with 665.1 nmol·min−1·mg−1 specific activity) and was incubated at 30 °C
with rocking for 20 min. NaCl (1 M) was added to stop the reaction, and
membranes were washed five times with water. To alkylate the thio-
phosphate, the membranes were incubated in 2.5 mM p-nitrobenzyl mesy-
late (Abcam) in water for 2 h at room temperature and then were washed
five times with water. To decrease background noise, membranes were in-
cubated in stripping solution (4 M Guanidine-HCl, 1% SDS, 0.5% β-mercap-
toethanol) for 1 h at 40 °C. Membranes were washed 10 times in water and
three times in TBST, blocked in 5%milk in TBST for 1 h at room temperature,
incubated with thiophosphate ester primary antibody (1:5,000; Abcam) in
5% milk in TBST overnight at 4 °C, and then were washed three times in
TBST. Membranes were then incubated for 45-min at room temperature
with IRDye 800CW goat anti-rabbit secondary antibody (1:10,000; LI-COR) in
5% BSA in TBST and were then washed three times in TBST and once in TBS.
The LI-COR Odyssey imaging system was used to visualize the array.
For in vitro kinase assays with unphosphorylated and S13p-primed
N17 peptide, 1,000 ng peptide (New England Peptides) was incubated in
1:5 KAB with 100 μM adenosine triphosphate (Sigma-Aldrich) or
N6FFA/kinetin triphosphate (Biolog) in a 10-μL reaction. The reaction was
initiated by the addition of CK2α holoenzyme (1:2,500, 32.44 mg/mL with
665.1 nmol·min−1·mg−1 specific activity) and was incubated at 30 °C for 15 min
with shaking. In each case, the reaction was stopped by placing it on ice, and
8 μL of the kinase assay mixture was spotted onto nitrocellulose membrane (Pall
Life Sciences) in 2-μL dots (×4) and allowed to dry for 30 min. Membranes were
washed once in TBST and blocked in 5% nonfat milk in TBST for 1.5 h and
then were incubated in anti–N17-S13pS16p (1:2,500) overnight at 4 °C with
rocking. Membranes were then washed three times in TBST and were incu-
bated with HRP-conjugated secondary antibody (1:50,000; Abcam) and were
visualized using Immobilon enhanced chemiluminesence (EMD Millipore) on a
MicroChemi system (DNR Bio-imaging Systems) or were incubated with IRDye
800CW goat anti-rabbit secondary antibody (1:10,000; LI-COR) and were visu-
alized on a LI-COR Odyssey system. The signal intensity of the dots was quan-
tified using ImageJ software.
Immunofluorescence. Cells were grown to ∼80% confluence in 96-well ibi-
Treat dishes (Ibidi) for screening or in glass-bottomed tissue-culture dishes
for irradiation experiments before the indicated treatments. Fixation and
permeabilization by methanol at −20 °C for 10 min was followed by washing
with wash buffer [50 mM Tris·HCl (pH 7.5), 150 mM NaCl, 0.1% Triton X-100]
and blocking for 1 h at room temperature with blocking buffer (wash buffer +
2% FBS). Cells were incubated with primary antibodies diluted in blocking
buffer for either 1 h at room temperature or overnight at 4 °C before washing
and imaging in PBS (Alexa Fluor 488-conjugated anti–N17-S13pS16p) or in-
cubation with secondary antibodies diluted in blocking buffer for 30 min at
room temperature. After washing, nuclei were stained with Hoechst (0.2 μg/mL
in PBS) for 5 min at room temperature, washed, and imaged in PBS. Cells
grown for SR-SIM imaging were seeded onto no. 1.5 coverslips, fixed and
stained as above, and mounted on glass slides using frame slide chambers
(Bio-Rad). Cells stained with the anti-N6FFA antibody were fixed and per-
meabilized in 1:1 methanol:acetone at −20 °C for 10 min, washed with PBS,
then incubated with 2 M HCl for 45 min at room temperature to denature
DNA. Following neutralization in 50 mM Tris·HCl (pH 8.8) for 5 min and
washing with PBS, cells were blocked and stained as above.
Induction of DNA Damage. For microirradiation experiments, cells were grown
overnight in glass-bottomed dishes and then were stained with NucBlue
(Molecular Probes/Life Technologies) for 15 min at 37 °C in a 5% CO2 in-
cubator. The medium was replaced with HBSS (Gibco) immediately before
microirradiation. Cells were irradiated using the Nikon C2+ confocal system
equipped with an InVivo Scientific environmental chamber held at 37 °C.
Regions of interest (∼20 pixels each) were irradiated at a scan speed of 16 s
per frame (512 × 512) using a Coherent OBIS 405-nm diode laser (Coherent,
Inc.) set to 100% power. The x and y coordinates were recorded, and cells
were incubated at 37 °C for the indicated periods before fixation and im-
munofluorescence. The x and y coordinates were then revisited to image the
irradiated cells.
Microscopy. Wide-field epifluorescence microscopy was done on a Nikon
Eclipse Ti wide-field epifluorescent inverted microscope using a PLAN FLUOR
40×/0.6 air objective (for screening), or a PLAN apochromat (APO) 60×/1.4 oil
objective and Spectra X LED lamp (Lumencor). Images were captured using a
Hamamatsu Orca-Flash 4.0 CMOS camera (Hamamatsu). Image acquisition
and deconvolution of Z-stacks were done with NIS-Elements Advanced Re-
search version 4.30 64-bit acquisition software (Nikon Instruments). Super-
resolution imaging was done on the Nikon N-SIM superresolution
microscope system attached to a Nikon Eclipse Ti inverted microscope using
an APO total internal reflection fluorescence (TIRF) 100×/1.49 oil objective
and 405-nm, 488-nm, and 561-nm lasers (Coherent, Inc.). Images were cap-
tured using a Hamamatsu Orca-Flash 4.0 CMOS camera and were acquired
with NIS-Elements software version 4.50.
Animal Care and N6FFA Trials. Male YAC128 mice overexpressing the human
HTT gene with 128 CAG repeats (39) were originally purchased from Jackson
Laboratories and subsequently were maintained on an FVB background in
the animal facility at the University of Alberta. All mice were maintained on
a 12-h/12-h light-dark cycle in a temperature- and humidity-controlled room.
All procedures involving animals were approved by the University of
Alberta’s Animal Care and Use Committee and were in accordance with the
guidelines of the Canadian Council on Animal Care. All YAC128 mice and WT
littermates used in our studies were males.
Treatment started between 6 and 10 mo of age, and motor testing began
14 d after the start of treatment. For experiments involving i.p. injection, all
mice were group housed for the duration of treatment. For experiments
involving oral administration, mice were individually housed for the duration
of treatment. Animals in all experimental groups were carefully matched
for age.
I.p. N6FFA Administration. Mice were 6–9 mo old at the beginning of treat-
ment. N6FFA (0.83 mg/kg or 4.17 mg/kg of body weight, in 1.5% DMSO in
saline solution) was administered daily at 1600 h by i.p. injection, alternating
the side of injection. Control mice were injected with 1.5% DMSO in saline.
Animals in all experimental groups were carefully matched for age (average
animal age ± SD: WT saline, 8.1 ± 1.08 mo; WT N6FFA 6 mg/kg, 7.51 ±
1.51 mo; WT N6FFA 30 mg/kg, 7.91 ± 1.31 mo; YAC128 saline, 7.2 ± 1.50 mo;
YAC128 6 mg/kg N6FFA, 7.2 ± 1.60 mo; YAC128 30 mg/kg N6FFA,
7.0 ± 1.57 mo).
Oral N6FFA Administration. Mice were 8–10 mo old at the beginning of
treatment. A chow diet supplemented with 653 mg N6FFA/kg chow






















(OpenSource Diets) was administered for 49 d. Each mouse was provided
with 10 g of chow diet, and food was replaced every second day, so that
food was available ad libitum. Food intake was measured every second day
at 1700 h. Body weight was measured weekly. Animals in all experimental
groups were carefully matched for age (average animal age ± SD: WT
control chow, 8.9 ± 0.68 mo; WT N6FFA chow, 9.0 ± 0.69 mo; YAC128 control
chow, 9.13 ± 0.74 mo; YAC128 N6FFA chow, 9.12 ± 0.69 mo).
Behavioral Tests. Behavioral testing was conducted in the light phase of the
light cycle, between 0800 h and 1800 h. In all behavioral training and testing
sessions, mice were allowed to acclimate to the testing room for 1 h. All
experiments were performed by experimenters who were blind to animal
genotype and treatment. All equipment was cleaned with 70% ethanol after
each test and before testing the next animal.
For the rotarod, mice were tested in three consecutive 3-min trials, with a
1-min rest between trials, at a fixed rotarod speed (12 rpm). The time spent on
the rotarod in each of the three trials was averaged to give the overall latency
to fall for each mouse. A similar training protocol was used to test mice on an
accelerating rotarod (4–40 rpm in 2 min). For the narrow beam test, mice
were placed at the extremity of a 100-cm-long wooden narrow beam
(0.75 cm wide, suspended 30 cm above the floor) and were allowed to tra-
verse the beam from one extremity to the other three times. Mouse per-
formance was recorded with a video camera, and footfalls, body balance,
and motor coordination were analyzed using an established footfall scoring
system (18). For the open field test mice were placed in an open field ap-
paratus (90 × 90 cm) and were filmed during 30-min sessions as they ex-
plored the environment. Distance traveled was measured using EthoVision
XT tracking software. At the end of each 30-min session in the open field,
the number of fecal pellets dropped by each mouse was counted. For the
elevated plus maze, mice were placed in the center of the maze facing the
open arm and were left to explore freely for 5 min. Arm crosses into and out
of open and closed arms, as well as time spent in each arm were recorded
with a video camera and scored. An entry was defined as 75% of the body of
the mouse, excluding the tail, entering a compartment.
The forced swim test was performed as in ref. 75 to assess anxiety through
the number of fecal boli dropped. Mice were placed for 6 min in a 4-L beaker
(25 cm tall, 16 cm wide) filled with 2.6 L of water prewarmed to 23–25 °C.
After each session, fecal pellets dropped by each mouse were counted.
Tissue Collection and Processing.Mice were killed by cervical dislocation. Brain
tissue was flash-frozen in liquid nitrogen and immediately homogenized in
ice-cold lysis buffer [20 mM Tris (pH 7.4), 1% Igepal, 1 mM EDTA, 1 mM EGTA,
50 μM MG132, 1× Roche cOmplete protease inhibitor mixture, and 1× Roche
PhosStop phosphatase inhibitor mixture] using a Wheaton homogenizer.
Tissue lysates were sonicated twice for 10 s each at power 2 using a Sonic
Dismembrator Model 100. Protein concentration was measured with the
bicinchoninic acid (BCA) assay.
Filter Retardation Assay. The filter retardation assay was performed as de-
scribed (39, 76), with minor modifications. Briefly, 100 μg of protein lysates
were diluted in PBS containing 2% SDS and 100 mM DTT, followed by heating
at 100 °C for 10 min. Samples were filtered through a cellulose acetate
membrane (0.2-μm pore size; Sterlitech) in a Bio-Dot microfiltration unit (Bio-
Rad). Wells were washed twice with PBS. After drying for 30 min, membranes
were washed twice with 2% SDS in PBS and thenwere blocked with 5%BSA in
TBST followed by incubation with the primary antibody. IRDye secondary
antibodies (LI-COR Biotechnology) were used at 1:10,000 for 1 h at room
temperature. The IR signal was acquired and quantified using the Odyssey
Imaging System.
Nuclear Condensation Toxicity Assay. The nuclear condensation assay to de-
termine toxicity of the N586 fragment of Htt in neurons was performed as
described (38). At 5 d in vitro, neurons were cotransfected with N586-Htt
containing either Q22 or Q82 and GFP for 48 h. At the time of transfection,
cells were treated with N6FFA doses ranging from 0 to 100 μM. After 48 h,
the cells were fixed with paraformaldehyde, and the nuclei were stained
with DAPI. Automatic image acquisition was obtained on an Axiovert
200 inverted microscope (Zeiss) using Axiovision. Nuclear staining intensity
of GFP+ cells was quantified automatically using Volocity (Perkin-Elmer). Any
cell with an intensity greater than two SDs of the control intensity of
untransfected cells was considered dead. Results are presented as a per-
centage of the total transfected cells.
Annexin V Cell Death Assay. STHdhQ7/Q7 and STHdhQ111/Q111 cells were plated
in 12-well plates and left to attach overnight. Cells were washed once with
Dulbecco’s PBS before incubation in serum-free medium (high-glucose
DMEM with 400 μg/mL geneticin, 2 mM L-glutamine, and 1 mM sodium
pyruvate) containing the indicated concentrations of N6FFA for 9 h at 39 °C.
At the end of the incubation period, cells were washed with PBS, trypsinized,
washed in PBS, and stained with annexin V PE (BD Pharmingen) in 45 μL of
1× annexin-binding buffer (ABB) (BD Pharmingen) for 15 min at room
temperature. Cells were then washed once with 1× ABB and fixed overnight
with 2% paraformaldehyde in 1× ABB. FACS analysis of annexin V+ cells was
performed using a CANTO II cell analyzer (BD). Ten thousand events per
sample were acquired and analyzed using either CellQuest Pro (BD) or
FlowJo analysis software.
Statistical Analysis. For mouse data, all statistical analyses were performed
using two-way ANOVA followed by Bonferroni posttest, except for the
analysis of body weight, for which repeated-measures two-way ANOVA
followed by Bonferroni posttests was used, and for changes in mutant
huntingtin expression, for which an unpaired t test was performed. All
comparisons were performed using a statistical significance level of 0.05. For
in vitro and cell-based assays, treatments were compared with control using
an unpaired two-tailed t test unless data did not pass the Shapiro–Wilk
normality test; in that case, Mann–Whitney analysis (two-tailed) was used.
Data and Materials Availability. All reagents and cell lines in this study are
available upon request.
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